学习与工作经历：

学习经历

• 2005/09-2008/07      复旦大学，中山医院肝脏外科，博士

• 2001/09-2004/07      山东大学，齐鲁医院普通外科，硕士

• 1996/09-2001/07      山东大学，临床医学院，学士

工作经历

• 2018/09-至今          山东大学，齐鲁医院肝胆外科主任医师，研究员，教授，博士研究生导师

• 2017/2-2018/08       山东大学，齐鲁医院肝胆外科研究员，教授，博士研究生导师，副主任医师

• 2013/09-2017/01      山东大学，齐鲁医院普外科副主任医师，硕士研究生导师

• 2008/08-2013/09      山东大学，齐鲁医院普外科，主治医师

研究方向：

肝癌基础与临床研究

学术/社会兼职：

山东大学齐鲁医院普外科主任，肝胆外科主任

山东省泰山学者特聘教授

中华医学会肿瘤学分会肝癌学组委员

中国医师协会外科医师分会肝脏外科专家工作组委员

中国抗癌协会胆道肿瘤整合康复专业委员会副主任委员

中国抗癌协会肝癌专业委员会常委

国家癌症中心肝癌质控专家委员会委员

国家癌症中心肝胆肿瘤质控专家委员会委员兼秘书

山东省医学会理事

山东省抗癌协会肝胆肿瘤分会候任主任委员

山东省医学会肝脏肿瘤多学科委员会副主任委员

山东省医师协会肝脏肿瘤多学科委员会副主任委员

山东省医师协会肝胆胰腔镜微创医师分会副主任委员

山东省医师协会普外多学科综合治疗专业委员会副主任委员

获奖荣誉：

山东省泰山学者

山东省十佳青年医师

山东大学齐鲁医学院名医体系—杰出青年医师

山东大学杰出中青年学者

济南市高校院所创新团队领军人才

本科生课程：

研究生课程：

外科学

循证医学

1.国家自然科学基金面上项目，82073200、Rab42调控肝癌外泌体HB-EGF分泌靶向作用于血管内皮细胞促进血管生成的机制研究、2021.01 - 2024.12，55万，主持

2.国家自然科学基金面上项目，81572328、TSC1/mTOR信号通路在TMPRSS4诱导肝癌血管生成中的作用研究、2016.01 -2019.12，66万，主持

3.国家自然科学基金面上项目，81874178，Rab42通过PI3K/Akt信号通路调控肝癌生长转移的作用及机制研究2019.01-2022.12，57万（直接经费），主持

4.国家自然科学基金青年项目，30901444、TMPRSS4诱导肝癌EMT发生的机制及其在预测肝癌复发转移及预后中的作用、2010.01-2012.12、20万元、主持

5.山东省泰山学者专项基金，tsqn20161064，肝癌血管生成相关靶基因的调控干预及其在预测肝癌复发转移中的作用研究、2017.01-2021.12，100万、主持

6.山东省自然科学基金重大基础研究，ZR2021ZD26，肝癌靶向药物耐药相关转录因子新靶标的功能研究、结构分析及靶向干预。2022.01- 2024.12, 200万，主持

7.山东省自然科学基金重点项目，ZR2014HZ002、MicroRNA-26介导的炎症信号通路对肝癌上皮间质转化的调控作用研究、2015.01-2017.12、28万元、主持。

8.肝癌血管生成调控机制创新团队（济南高校20条），2020GXRC023、2021.01-2023.12, 90万、主持

1.Li RZ, Pan GQ, Xiong C, Ding ZN, Zhang TS, Yan LJ, Wang D, Zhang X, Dong XF, Yan YC, Zhou Y, Dong R, Dong ZR, Li T. Hypoxia-Induced Creatine Uptake Reprograms Metabolism to Antagonize PARP1-Mediated Cell Death and Facilitate Tumor Progression in Hepatocellular Carcinoma. Cancer Res 2025;85(19):3671-3688.(Corresponding author)

2.Qu Y, Chen C, Sun F, Liu S, Zhao G, Zhao Z, Liu C, Jiang X, Li T. Epigenetic modulation with nanosatellite triggers tumoricidal immunity for hepatocellular carcinoma treatment. Nat Commun 2025;16(1):7340. (Corresponding author, SCI)

3.Pan GQ, Yan YC, Li RZ, Xiong C, Zhang SP, Qu Y, Dong R, Zhou Y, Zhang TS, Chen ZQ, Zhang XL, Dong XF, Wang DX, Dong ZR,Li T. Targeting SAMD1 enhances the effect of anti-PD-1 plus lenvatinib therapy in hepatocellular carcinoma by increasing ferroptosis sensitivity and immune response. Metabolism 2025:156304. (Corresponding author,)

4.Pan GQ, Yan YC, Li RZ, Dong ZR, Li T. Response to "expanding the clinical and Immunogenomic relevance of SAMD1 in hepatocellular carcinoma". Metabolism. 2025:156336. (Corresponding author)

5.Wang Q, Zhang X, Han C, Lv Z, Zheng Y, Liu X, Du Z, Liu T, Xue D,Li T, Wang L. Immunodynamic axis of fibroblast-driven neutrophil infiltration in acute pancreatitis: NF-κB-HIF-1α-CXCL1. Cell Mol Biol Lett. 2025 May 7;30(1):57 (Corresponding author, SCI)

6.Yan YC, Shao LJ, Meng GX, Pan GQ, Li RZ, Xiong C, Liu SJ, Ding ZN, Zhang XL, Dong XF, Qu Y, Dong ZR, Li T.Targeting FAM111B attenuates mitophagy and increases the sensitivity to lenvatinib treatment by increasing MFN2 stability in hepatocellular carcinoma. Cell Death Dis. 2025 Aug 25;16(1):645. (Corresponding author)

7.Pathomics-Integrated Multimodal Model Evaluate Chemoimmunotherapy Efficacy in Unresectable Intrahepatic Cholangiocarcinoma. JHEP Rep 2025;7(11):101557.(Corresponding autho)

8.Feifei Sun, Yuchuan Yan, Deqing Sun, Shijia Liu, Zhaoru Dong, Guogiang Pan, Yi Ou, Tao Li. Targeting CAMK1D-engineered nanoactivator suppresses cancer stem cell mairresistant prostate cancer. Theranostics 2025, 10.7150/thno.120826. (Corresponding author)

9.Lu D, Li H, Sun P, Tian J, Jiao K, Cao Q, Wang Y, Jia J, He Q, Peng S, Zhang D, Dong Z, Wang D, Li T. Systemic therapy plus HAIC versus systemic therapy for hepatocellular carcinoma: a systematic review and meta-analysis. Int J Surg. 2025 May 1;111(5):3494-3507. (Corresponding author)

10.Associated Factors Identification and Predictive Model Development for Perioperative Risk in Patients with Hepatocellular Carcinoma Receiving Preoperative Immunotherapy. HBSN 2025，(Corresponding author)

11.Yang CC, Yan YC, Pan GQ, Meng GX, Zhang X, Yan LJ, Ding ZN, Wang DX, Li RZ, Li GZ, Dong ZR,Li T. Thyroid hormones inhibit tumor progression and enhance the antitumor activity of lenvatinib in hepatocellular carcinoma via reprogramming glucose metabolism. Cell Death Discov. 2025 Mar 8;11(1):92. (Corresponding author,)

12.Yan ZB, Han CL, Jia JS, Li H, Lu DH, Cao QH, Wang YX, Jiao KF, He Q, Peng SX, Zhang DL, Wang Q, Li T. The landscape of gut microbiota in hepatocarcinogenesis: a comprehensive review of pathogenesis and therapeutic interventions. Int J Surg. 2025 Sep 24. doi: 10.1097/JS9.0000000000003511. (Corresponding author)

13.Ying Qu, Jingjing Zhao, Long Ma, Xue Wang, Feifei Sun, Yizhe Li, Yihua Wu, Guozhi Zhao, Shijia Liu, Wenqing Ma, Tao Li, Zhongxi Zhao. Intranasal delivery of temozolomide and disulfiram in situ gel combined with copper for enhanced glioblastoma therapy. Colloids and Surfaces B: Biointerfaces, 2025: 255,114898(Corresponding author)

14.Wang Q, Han C, Zheng Y, Liu X, Lv Z, Du Z, Liu T, Hao C, Meng X, Li T, Xue D. Silymarin ameliorates diet-induced gallstone formation by regulating gut microbiota-derived GCDCA to suppress ferroptosis-ROS-NFκB signaling pathway. Free Radic Biol Med 2025;239:496-512. (Corresponding author)

15.Wang DX, Long JY, Li RZ, Zhang DL, Liu H, Liu J, Tian JC, Li H, Liu J, Zhao HT, Li T. Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments. Mol Cancer. 2024;23(1):15. (Corresponding author)

16.Liu H, Li H, Wang DX, Li T. Letter to the Editor: Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis. Hepatology. 2024 May 1;79(5):E144-E145 (Corresponding author)

17.Wang DX, Liu H, Tian JC, Zhang DL, Yan LJ, Ding ZN, Li H, Yan YC, Dong ZR, Li T. Neoadjuvant immunotherapy based on PD-1/L1 inhibitors for gastrointestinal tumors: a review of the rationale and clinical advances. Int J Surg. 2024 Jun 1;110(6):3707-3722 (Corresponding author)

18.Dong ZR, Zhang MY, Qu LX, Zou J, Yang YH, Ma YL, Yang CC, Cao XL, Wang LY, Zhang XL,Li T. Spatial resolved transcriptomics reveals distinct cross-talk between cancer cells and tumor-associated macrophages in intrahepatic cholangiocarcinoma. Biomark Res. 2024 ;12(1):100. (Corresponding author)

19.Tan S, Zhang X, Guo X, Pan G, Yan L, Ding Z, Li R, Wang D, Yan Y, Dong Z, Li T.DAP3 promotes mitochondrial activity and tumour progression in hepatocellular carcinoma by regulating MT-ND5 expression. Cell Death Dis. 2024;15(7):540. (Corresponding author)

20.Liu SJ, Yan LJ, Wang HC, Ding ZN, Liu H, Zhang X, Pan GQ, Han CL, Tian BW, Yang XR, Tan SY, Dong ZR, Wang DX, Yan YC, Li T. Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis. Oncologist. 2024;29(11):e1425-e1434 (Corresponding author)

21.Dong ZR, Sun D, Yang YF, Zhou W, Wu R, Wang XW, Shi K, Yan YC, Yan LJ, Yao CY, Chen ZQ, Zhi XT,Li T. TMPRSS4 Drives Angiogenesis in Hepatocellular Carcinoma by Promoting HB-EGF Expression and Proteolytic Cleavage. Hepatology2020; 72:923-939 (Corresponding author)

22.Guo X, Tan S, Wang T, Sun R, Li S, Tian P, Li M, Wang Y, Zhang Y, Yan Y, Dong Z, Yan L, Yue X, Wu Z, Li C, Yamagata K, Gao L, Ma C,Li T, Liang X. NAD+ salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity. Hepatology 2023，78(2): 468-485.(co-Corresponding author).

23.Wang DX, Liu H, Tian JC, Zhang DL, Yan LJ, Ding ZN, Li H, Yan YC, Dong ZR, Li T. Neoadjuvant immunotherapy based on PD-1/L1 inhibitors for gastrointestinal tumors: a review of the rationale and clinical advances. Int J Surg. 2024 ;110(6):3707-3722 (Corresponding author)

24.Mao XC, Shi S, Yan LJ, Wang HC, Ding ZN, Liu H, Pan GQ, Zhang X, Han CL, Tian BW, Wang DX, Tan SY, Dong ZR, Yan YC,Li T. A model based on adipose and muscle-related indicators evaluated by CT images for predicting microvascular invasion in HCC patients. Biomark Res 2023;11(1):87. (Corresponding author)

25.Yan YC, Meng GX, Yang CC, Yang YF, Tan SY, Yan LJ, Ding ZN, Ma YL, Dong ZR,Li T. Diacylglycerol lipase alpha promotes hepatocellular carcinoma progression and induces lenvatinib resistance by enhancing YAP activity. Cell Death Dis 2023;14(7):404. (Corresponding author)

26.Lun-Jie Yan, Long-Shan Yang, Yu-Chuan Yan, Si-Yu Tan, Zi-Niu Ding, Hui Liu, Dong-Xu Wang, Zhao-Ru Dong,Tao Li. Anthropometric Indicators of Adiposity and Risk of Primary Liver Cancer: A Systematic Review and Dose-Response Meta-analysis. European Journal of Cancer 2023；185:150-163.(Corresponding author)

27.Dong ZR, Ke AW,Li T, Cai JB, Yang YF, Zhou W, Shi GM, Fan J. CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity. Mol Cancer2021;20(1):75. (Co-first author)

28.Dong ZR, Cai JB, Shi GM, Yang YF, Huang XY, Zhang C, Dong RZ, Wei CY, Li T, Ke AW, Fan J. Oncogenic miR-93-5p/Gal-9 axis drives CD8 (+) T-cell inactivation and is a therapeutic target for hepatocellular carcinoma immunotherapy. Cancer Lett 2023;564:216186. (Corresponding author)

29.Ding ZN, Meng GX, Xue JS, Liu H, Yang LS, Li RZ, Mao XC, Yan YC, Wang DX, Dong ZR,Li T. Systemic Therapy With or Without Locoregional Therapy for Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. Crit Rev Oncol Hematol 2023; 184:103940. (Corresponding author)

30.Li GZ, Meng GX, Pan GQ, Zhang X, Yan LJ, Li RZ, Ding ZN, Tan SY, Wang DX, Tian BW, Yan YC, Dong ZR, Hong JG,Li T. MALAT1/ mir-1-3p mediated BRF2 expression promotes HCC progression via inhibiting the LKB1/AMPK signaling pathway. Cancer Cell Int 2023;23(1):188. (Corresponding author).

31.Han CL, Tian BW, Yan LJ, Ding ZN, Liu H, Mao XC, Tian JC, Xue JS, Tan SY, Dong ZR, Yan YC, Hong JG, Chen ZQ, Wang DX,Li T. Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients. Cancer Immunol Immunother 2023; 72(7):1957-1969. (Corresponding author)

32.Tian BW, Han CL, Dong ZR, Tan SY, Wang DX,Li T. Role of Exosomes in Immunotherapy of Hepatocellular Carcinoma. Cancers (Basel) 2022, 21;14(16):4036. (Corresponding author)

33.Tian BW, Yang YF, Yang CC, Yan LJ, Ding ZN, Liu H, Xue JS, Dong ZR, Chen ZQ, Hong JG, Wang DX, Han CL, Mao XC,Li T. Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis. Immunotherapy 2022, 14(18):1481-1496. (Corresponding author)

34.Ma YL, Yang YF, Wang HC, Yang CC, Yan LJ, Ding ZN, Tian BW, Liu H, Xue JS, Han CL, Tan SY, Hong JG, Yan YC, Mao XC, Wang DX,Li T. A novel prognostic scoring model based on copper homeostasis and cuproptosis which indicates changes in tumor microenvironment and affects treatment response. Front Pharmacol. 2023;14:1101749. (Corresponding author)

35.Tian BW, Yan LJ, Ding ZN, Liu H, Han CL, Meng GX, Xue JS, Dong ZR, Yan YC, Hong JG, Chen ZQ, Wang DX,Li T. Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis. Int Immunopharmacol 2022, 30;114:109519. (Corresponding author)

36.Liu H, Yang CC, Ma YL, Yang YF, Yan LJ, Ding ZN, Xue JS, Yang LS, Yan YC, Dong ZR, Wang DX, Chen ZQ, Hong JG, Li T. Identification of the most effective subgroup of advanced hepatocellular carcinoma from immune checkpoint blocker treatment: a meta-analysis. Imm, SCI, IF:2.8)

37.Yang LS, Yan LJ, Yan YC, Ding ZN, Liu H, Tan SY, Dong ZR, Wang DX, Li T. Regional and sex differences in the mortality risk associated with primary liver cancer in obesity: A systematic review and meta-analysis. Nutrition 2023,113:112097. (Corresponding author)

38.Mao XC, Yang CC, Yang YF, Yan LJ, Ding ZN, Liu H, Yan YC, Dong ZR, Wang DX,Li T. Peripheral cytokine levels as novel predictors of survival in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front Immunol 2022,22;13:884592. (Corresponding author)

39.Ding ZN, Dong ZR,ChenZQ, Hong JG,YanLJ, Li HC, Yao SY, Yan YC, Yang YF, Yang CC,LiT. Viral status and efficacy of immunotherapy in hepatocellular carcinoma: A systematic review with meta-analysis. Front Immunol. doi: 10.3389/fimmu.2021.733530. (Corresponding author)

40.Han-CL, Meng GX, Ding-ZN, Dong ZR, Chen-ZQ, Hong JG, Yan LJ, Liu H, Tian BW, Yang LS, Xue JS,Li T. The Predictive Potential of the baseline C-reactive protein levels for the efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. Front Immunol,2022.13:827788. (Corresponding author)

41.Xue JS, Ding ZN, Meng GX, Yan LJ, Liu H, Li HC, Yao SY, Tian BW, Dong ZR, Chen ZQ, Hong JG, Wang DX,Li T.The prognostic value of natural killer cells and their receptors/ligands in hepatocellular carcinoma: a systematic review and meta-analysis. Front Immunol,2022.872353. (Corresponding author).

42.Xue JS, Liu H, Meng GX, Ding ZN, Yan LJ, Yao SY, Li HC, Dong ZR, Chen ZQ, Hong JG,Li T. Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis. Cancer Immunol Immunother. 2022;71(7):1633-1644. (Corresponding author)

43.Yang CC, Meng GX, Dong ZR,Li T. Role of Rab GTPases in Hepatocellular Carcinoma.J Hepatocell Carcinoma.2021;8:1389-1397. (Corresponding author)

44.Yan LJ, Yao SY, Meng GX, Liu KX, Li HC, Ding ZN, Dong ZR, Hong JG, Chen ZQ,Li T. Sex and regional disparities in incidence of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis. Hepatol Int 2021;15:1413-1420. (Corresponding author)

45.Yu B, Zhi X, Li Q, Xu B, Dong Z,Li T, Chen Z. The efficacy and safety of preoperative cholangiography via percutaneous transhepatic gallbladder drainage for difficult laparoscopic cholecystectomy. Surg Endosc.2022, 36:1355–1361 (Corresponding author).

46.Su P, Hong J,Li T.An Uncommon Lesion of the Liver. Gastroenterology. 2021:7:2258-2260. (Corresponding author).

47.Dong ZR, Zhi XT,Li T. A rapidly progressing polycystic liver disease? Gastroenterology 2020;158(1):e9-e11. (Corresponding author)

48.Jin B,Du G,Li T. Right upper abdominal distension and discomfort caused by a massive hepatic tumor. Gastroenterology 2017, 153:e24-e26. (Corresponding author)

49.Jiang RD, Zhang ZL,Li T. Abdominal pain caused by spontaneous rupture of a liver tumor. Gastroenterology 2015,149:35-36. (Corresponding author)

50.Li T. An incidentally discovered abdominal mass during physical examination. Gastroenterology 2016, 151:e16-7. (Corresponding author)

51.Xiang TG, Liu GX,Li T. An unusual cause of life-threatening upper gastrointestinal bleeding. Gastroenterology 2016;151:400-2. (Corresponding author)

52.Jiang RD, Zhang ZL,Li T. Calcified Cyst in the Spleen. JAMA Surg 2016, 151:675-6. (Corresponding author)

53.Li T, Hao CY, Zhang ZL. Hematochezia caused by a colon disease with unusual presentation. Gastroenterology 2018;154(4):e1-e3 (Corresponding author).

54.Li T, Wang SK, Zhou J, Sun HC, Qiu SJ, Ye QH, Wang L, Fan J. PositiveHBcAb is associated with higher risk of early recurrence and poorer survival after curative resection of HBV-related HCC. Liver Int 2016,36:284-92（Corresponding author）

55.Li T, Dong ZR, Guo ZY, Wang CH, Zhi XT, Zhou JW, Li DK, Chen ZT, Chen ZT, Hu SY. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway. Liver Int 2015;35:1416-29（Corresponding author）

56.Jiang RD, Jian WC, Jin N, Zhang ZL,Li T. Tumor lysis syndrome a serious complication of transcatheter arterial chemoembolization for hepatocellular carcinoma. Am J Med 2016; 129:e173-6. (Corresponding author)

57.Zhi XT, Hong JG, Li T, Sun D, Yu DX, Chen ZQ,Li T. Gastric Crohn's disease: a rare cause of intermittent abdominal pain and vomiting. Am J Med 2017;130(5):e181-e185. (Corresponding author)

58.Li T, Ji Y, Zhi XT, Wang L, Yang XR, Shi GM, Zhang W, Tang ZY. A Comparison of Hepatic Mucinous Cystic Neoplasms With Biliary Intraductal Papillary Neoplasms. Clin Gastroenterol Hepatol 2009; 7:586-593. (Corresponding author)

59.Li T, Zhi XT, Hu SY. Congenital portal venous system aneurysms associated with caput medusae. Hepatology 2011; 53:1052-1053 (Corresponding author)

60.Li T, Qin LX, Gong X, Zhou J, Sun HC, Qiu SJ, Ye QH, Wang L, Fan J.Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Cancer 2013; 119:126-135 (Corresponding author)

61.Li T, Qin LX, Zhou J, Sun HC, Qiu SJ, Ye QH, Wang L, Tang ZY, Fan J. Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection. Liver Int 2014;34:953-960.（Corresponding author）

62.Li T, Fan J, Qin LX, Zhou J, Sun HC, Qiu SJ, Ye QH, Wang L, Tang ZY. Risk factors, prognosis and management of early and late intrahepatic recurrence after resection of primary clear cell carcinoma of the liver. Ann Surg Oncol 2011; 18:1955-1963 (Corresponding author)

63.Li T, Qin LX, Gong X, Zhou J, Sun HC, Wang L, Qiu SJ, Ye QH, Fan J. Clinical Characteristics, Outcome and Risk Factors for Early and Late Intrahepatic Recurrence of Female Patients after Curative Resection of Hepatocellular Carcinoma. Surgery 2014;156:651-660 ( Corresponding author)

64.Li T, Zeng ZC, Wang L, Qiu SJ, Zhou JW, Zhi XT, Yu HH, Tang ZY.Radiation enhances long-term metastasis potential of residual hepatocellular carcinoma in nude mice through TMPRSS4-induced epithelial-mesenchymal transition. Cancer Gene Ther 2011;18:617-626 (Corresponding author)

65.Li T, Dong ZR, Guo ZY, Wang CH, Tang ZY, Qu SF, Chen ZT, Li XW, Zhi XT.Aspirin enhances IFN-a-induced growth inhibition and apoptosis of hepatocellular carcinoma via JAK1/STAT1 pathway. Cancer Gene Ther 2013; 20, 366-374 (Corresponding author)